Circulating Tumor DNA Cancer Detection Method

Over 8.2 million people die of cancer each year due to the bad accessibility to detection methods and treatment. The problem is that people are finding out they have cancer too late which makes it harder to treat. Cancer is the 4th most leading cause of death between adults 20-39 years old in the United States. Nearly half of people who have cancer aren’t diagnosed early enough. This makes it harder for the treatment to succeed, making it more likely for the patient to die. Circulating tumor DNA can help detect cancer cells quite early on. Once a cancer has spread it makes it a lot harder to treat and get rid of. Circulating tumor DNA cancer detection method can help doctors identify if a patient has the cells for cancer. The most important part about this technology is that it can identify cancer cells before there’s a tumor. This technology can help doctors start treating the patient quickly which will increase their risk of survival and increase the chance of the treatment being successful.

Cancer cells break down during their life allowing ctDNA to be released into someone’s bloodstream. A liquid biopsy is also called ctDNA examination of a blood sample. It can notice and spot cancer-related to mutations. Solid biopsies cannot show tumor dynamics or sensitivity to the treatment because they are invasive and cannot always be done effectively. It’s better to develop a less invasive detection method. Circulating tumor DNA cancer detection method can be a good alternative. Circulating tumor DNA comes from cancerous tumors and cells. Cells die as the tumor grows and cells are restored by new ones. The dead cells break down and the DNA is released in the bloodstream. Circulating tumor DNA very small pieces of DNA. A biopsy sample of tissue is often tested for specific genetic variation (also called mutations).

Circulating tumor DNA is extracted in a non-invasive way using a blood sample. Doctors are required to have approximately 3ml of blood in EDTA coated tubes. EDTA tubes are important to lower coagulation of blood. The serum and plasma factors of blood can be split up using a centrifugation step. Circulating tumor DNA can then be extracted from these fractions. Most studies use plasma for ctDNA. To remove residual intact blood cells, plasma is prepared again by centrifugation. The supernatant is used to get the DNA, which can be done using special kits. Many different amplification and sequencing methods are needed for the examination of ctDNA after removal. These methods then can be divided into two different groups depending on if the goal is to interrogate all genes in a non-targeting manner, or if the goal is to monitor and observe certain mutations and genes.

Advantages

  • Circulating tumor DNA cancer detection method can be very advantageous because it’s detected in the blood and it’s less invasive and risky for multiple tumor biopsies, and to monitor and track the tumor.
  • Evidence shows that there is a big chance that ctDNA cancer detection method can benefit and improve the early detection of a tumor and the treatment.
  • By searching for ctDNA in the blood can point out key molecular markers which can be missed out if another tissue biopsy is hard to follow.
  • Test results are generally available earlier than tissue biopsy. Doing a liquid biopsy makes it possible for doctors to make an early diagnosis.
  • To approximate the risk for metastatic progression or metastatic relapse liquid biopsies can be done.
  • Circulating tumor DNA can often be repeated and can be done as often as necessary if the patient’s tumor progresses or if doctors want to monitor the cancer.
  • Liquid biopsy costs less than tissue biopsies.

Disadvantages

  • Some cancer patients have little tissue left after a liquid biopsy, which might not be enough for the genetic testing that could form the cancer treatment later.
  • Tumors can be dangerous and difficult to reach after more than one biopsy.
  • In the blood it’s hard to detect small quantities of DNA variation, mainly when the patient has a small volume of the cancer.
  • Tests can come out negative if the patient’s cancer volume is too small.
  • Circulating tumor DNA tests can cost thousands of dollars. Insurance coverage is variable. This can be hard for people who cannot afford the expensive test, but would like to get tested.
  • Liquid biopsy procedures aren’t as well known and done as tissue biopsy. More verification is necessary to find the real value of liquid biopsies in the medical world to support the clinical benefit of the test.
  • More studies are needed to identify whether the test is accurate enough and its ability to identify certain tumors.
  • Test sensitivity challenges also exist. Circulating tumor cells are quite rare compared to the hematological molecules found in someone’s blood sample, there are challenges to the test’s accurate enough detection ability.

Personal Opinion

I think ctDNA cancer detection method is a better alternative from tissue biopsy because it’s less invasive but it can still detect ctDNA just as well. However, the test might come back negative if the patient’s cancer volume is too small, which is a disadvantage for the patient because the test is expensive and they might want to do it again. Nevertheless, the technology has lots of advantages which make it beneficial.

Liquid biopsy is offered and developed in a number of small laboratories in the UK. In 2018 there were a total of 316,680 cancer diagnoses in the UK. Because the tests aren’t very well known and developed yet so many people don’t do them. Cancer is a genetically inherited disease and if a patient’s test comes back negative but someone in their family has had cancer before they might want to do the test again. The test costs 1,200$ which is very expensive for some people especially if they have to do it more than once. The poverty rate in the year 2018 was 11.8% in the USA. Meaning almost 12% of the US population likely couldn’t afford to do the test again or to even do the test the first time. This connects to the economic factor because the test is expensive and not everyone can afford it. Moreover, ctDNA testing is still being developed which makes it inaccessible for many people.

Summarizing, I believe that ctDNA testing is very beneficial for the world and cancer patients. It has a big potential for helping detect cancer and help cancer patients survive in the future.

Cancer Treatments During Pregnancy

Oncological treatment and pregnancy are possible, but not excluding some short-term and long-term effects on the unborn child. Cancer treatment can be categorized as surgery, radiation therapy, and chemotherapy.

Surgery is a crucial part of treating cancer. With special precautions, surgery is possible during pregnancy, although not without the added risk of miscarriage, premature delivery, and fetal distress. During surgery, the mother is at risk of hypotension, hypoglycemia, hypoxia or stress, adding a greater risk to the fetus then the possible risks of anesthesia (Vandenbrouke, Verheecke, Fumagalli, Lok & Amant, 2017).

Radiation therapy uses high energy x-ray to shrink tumors and destroy cancer cells. Radiation is not recommended during pregnancy due to the harmful effects on the rapidly growing fetus, causing death or malformations. From animal studies and atomic bomb survivors that were exposed to radiation, findings showed growth restrictions and organ defects of the fetus (Vandenbrouke, Verheecke, Fumagalli, Lok & Amant, 2017). A stochastic effect of radiation therapy is an increased risk of childhood cancers.

Chemotherapy is a cytotoxic drug, interfering with cell growth. Potential risks of the fetus are malformation, preterm labor and effects the child to adulthood causing hematological problems, cardiac problems, neurocognitive dysfunction, hearing impairment, dental deformities, behavior issues, fertility problems and cancer (Vandenbrouke, Verheecke, Fumagalli, Lok & Amant, 2017).

Resources

Not only does cancer and cancer treatments affect the fetus, but also affects the mother physically, mentally and spiritually. Depending on the type, stage, and aggressiveness of cancer, the mother may not have the option to postpone treatment in order to stay alive, resulting in the option of aborting the unborn child to continue treatment. This can go against the mother’s religious preferences, severely affecting her emotional wellbeing.

Expecting mothers have different resources like therapy and support groups to help them continue their journey through cancer. ‘Hope for Two’ is a nonprofit cancer network for women diagnosed with cancer during pregnancy, where they provide support, offer hope and share experiences with one another through phone and email conversations, serving all religious backgrounds worldwide, providing respect and support without judgment to every woman’s personal decision.

Mothers can also receive information regarding their options from their doctors or by the recourses that the American Cancer Society or the American Society of Clinical Oncology provides. The American Cancer Society and American Society of Clinical Oncology Provide accurate information regarding specific cancer diagnosis, different treatment options and support group information.

My Idea

Education is the most important resource that can be provided. Properly educating expecting mothers and giving them every option, can offer them the knowledge to make a confident and educated decision that is best for their specific situation. Unfortunately, there is not enough research provided to support the different options available.

Those that are willing to treat during pregnancy, the fetus will be studied. Adding on to the current research that is provide, but researching more specifically on the long-term effects of the different types of treatments regarding the different diagnoses. The ongoing collection of data would be long term, assessing the different outcome of the fetus when they are adults. What complications arouse during their life time? Did the treatments cause cancer? If so what type of cancer is most common? What age did the cancer start growing? Is it more aggressive in contrast to someone who did not undergo intrauterine cancer treatments?

Once enough evidence is evaluated, expecting mothers have more information to help them make an educated decision regarding what treatment option is best for them and their unborn child.

For a short-term idea, those planning pregnancy should be educated to undergo preventative cancer screenings. By doing so, you are able to identify and provide treatment to an early cancer giving the parents knowledge to postpone pregnancy until treatment is over.

Young parents may also test their genes with genetic testing to assess their potential of getting cancer, and base their pregnancy plans according to their results. If the potential is high, couples could choose to postpone pregnancy, possibly preserving the eggs through embryo cryopreservation.

My Personal Learning

During my research, I have found that there is not much evidence supporting the effects of different treatments. Because of this, mothers cannot confidently choose a treatment plan that is best for her and her child during her fight through cancer. Further research is needed to determine the safety of the different cancer treatments and the short term and long-term effects it has on the fetus.

Knowledge helps avoid delay of maternal treatment, termination of the fetus or induction of preterm delivery. An informed discussion can be made when outcome data is provided to the patient.

References

  1. American Cancer Society. (n.d.). Retrieved from https://www.cancer.org/
  2. Hope for Two…The Pregnant with Cancer Network. (n.d.). Retrieved from http://www.hopefortwo.org/
  3. Last American Society of Clinical Oncology. (n.d.). Retrieved from https://www.cancer.net/
  4. Vandenbroucke, T., Verheecke, M., Fumagalli, M., Lok, C., & Amant, F. (2017, November). Effects of Cancer Treatment During Pregnancy on Fetal and Child Development [Scholarly project]. Retrieved from http://www.thelancet.com/child-adolecent

Coping with Child’s Cancer

Coping with a child who has a disease, such as cancer, can be a complex, psychological, and behavioral process that affects not only the patient, but the family as well. Cancer can cause emotional distress such as anxiety, stress, and difficulty coping. This quantitative article examines the coping strategies, religious attitudes, and optimism of mothers who have children with cancer.

Correlation to Nursing

Not only are diseases relevant to nursing, but also have an effect on the patient and their family. As nurses, we are not only treating the disease, but caring for the patient and providing the utmost amount of quality care. Cancer is a different kind of disease in itself, and can endure hopelessness in patients and their families in lieu of scientists still researching a cure. For a mother, it is especially important that she utilizes adequate coping and optimism for her and her family. Children tend to lean on their mothers in times of need, and mothers have a special bond after giving birth. The emotions of the mother and family members can greatly affect the patient’s mindset, therefore affecting the patient’s vulnerable state. Most chronic diseases have similar effects on family members including psychological and emotional functioning, disruption of leisure activities, effect on interpersonal relationships, and financial resources (Golics et al., 2015). By studying the results of the research conducted, nurses may be able to better understand the effect of religion on the care of mothers with children with complex diseases such as cancer and improve the spiritual care in nursing (Bozkurt et al., 2019).

Research Method

This study collects demographic data on the mothers and children participating and examines if there are any correlations between this data and the subjects’ feelings on religion, levels of optimism, and coping mechanisms as well as the relationship between these three factors (Bozkurt et al., 2019). In an attempt to answer these two research questions and confirm the hypothesis regarding coping mechanisms, the researchers conducted their methodologies with several independent and dependent variables. The independent variables of the study are mothers who are at least 18 and have children diagnosed with cancer at least 1 month prior to the study who are undergoing treatment. The dependent variables are the coping mechanisms, religious attitudes, and optimism of the mothers (Bozkurt et al., 2019). The setting of this study was the pediatric hematology oncology clinic of a university hospital in Istanbul and the population was all mothers who had children with cancer that were admitted to the clinic and met the sample selection criteria in 1 year (Bozkurt et al., 2019).

Data Collection

With this population and setting, this correlational and cross-sectional study used the methodology of a demographic questionnaire, coping strategy questionnaire, religious attitude scale, and life orientation test-revised. The advantages of using a correlational and cross-sectional study are that, respectively, they allow researchers to study variables that would otherwise be unethical to control and are not time-consuming or expensive to conduct. Conversely, some disadvantages are that a correlational study has little control over the extraneous variables and a cross-sectional study runs the risk of non-response (LoBiondo & Haber, 2018).

Still being able to work with these advantages and disadvantages, the data was collected by inviting this group of mothers who met the criteria needed and administering questionnaires and analyzing the data to see the correlation it had with coping, religion, and optimism.

Instruments Used

The Demographic Questionnaire was used to assess the characteristics of the participants, including education, occupation, sex, age, medical procedures, and diagnosis time of the disease” (Bozkurt et al., 2019). This questionnaire is both reliable and valid in that it consists of standard questions asking about age, sex, occupation, education, medical procedures, and time of diagnosis. These factors are validified in regards to socioeconomic status due to the variation of topics asked. The Coping Strategy Questionnaire (CSQ) used a scale of 33 items to measure efficient coping with a higher score signifying greater efficiency. This questionnaire is not as reliable or valid as the first due to the fact that some answers may have been skewed from the mothers potentially providing answers, they believed were more acceptable rather than being honest with how they felt. The Religious Attitude Scale (RAS) determines the extent of religion in the lives of the subjects with a higher numerical score indicating increased levels of religious attitude. The Life Orientation Test-Revised (LOT-R) used five items to determine a numerical value that reflected optimistic attitude (Bozkurt et al., 2019).

Following review of the different forms of data collection used, we are better able to understand the findings of the study. After examining the correlations between working status, children’s sex, number of children, and the scores of the CSQ, RAS, and LOT-R, there was no statistical significance found. There was also no statistical significance in the correlations between mothers’ education level and the scores of the CSQ and LOT-R. It was observed that mothers with low educational levels had statistically significantly higher scores of religious attitudes. There was a positive correlation between the children’s age and duration since disease diagnosis the scores of RAS, yet oppositely a negative correlation between that and the scores of LOT-R. Additionally, there were correlations examined between the scores of the mothers from CSQ, RAS, and LOT-R and the scores from the subscales of these scales. There was found to be positive correlations between the total score of CSQ and emotional scores of RAS and also between the CSQ Social Support Seeking subscale and total scores of RAS and LOT-R (Bozkurt et al., 2019).

Conclusions

While these study findings highlight the potential positive effects of religiosity on well-being, the results still indicated that the correlational relationship between mothers’ religious beliefs, coping mechanisms, and optimistic attitudes was not significant (Bozkurt et al., 2019). This may be due to the limitations and weakness of the study which included its cross-sectional design and lack of a control group. The control group could have helped to rule out alternatives in this study. The insufficient sample size is also one of the main reasons why there were no relationships determined between religious tendencies, coping, and optimism. It must also be taken into consideration that participant responses may not be representative of the target population being studied and that these results cannot be generalized to all mothers of children with cancer (Bozkurt et al., 2019). The level of evidence is not strong enough to have a conclusive study. Due to the weaknesses observed, it is evident that results are not able to determine the effect of religion on the coping of mothers of children with cancer in different cultures and religions. Therefore, further studies need to be done to determine this.

Recommendations for Future Research and Education

After reading and evaluating this research, it is recommended that further research and studies should investigate the effect of religion on coping mothers who have children with cancer. Different cultures and religions should be studied, as these results are generalized. Certain religions or cultures may restrict coping techniques. Testing in different socioeconomic areas could also alter results, and give a new perspective. Mothers in low or poor socioeconomic areas may not have as many resources in regards to coping and group therapy. The authors’ recommendation is to examine the effect of religious attitudes on coping through social experiments and to do so in different socioeconomic levels. The authors believe this continued research will help in understanding the influence of religion in different cultures and improving spiritual care.

References

  1. Bozkurt, G., Inal, S., Yantiri, L., & Alparslan, Ö. (2019). Relationship Between Coping Strategies, Religious Attitude, and Optimism of Mothers of Children With Cancer. Journal of Transcultural Nursing. 30(4), 365-370. doi: 10.1177/1043659618818714.
  2. Golics, C. J., Basra, M. K., Finlay, A. Y., & Salek, S. (2015). The Impact of Disease on Family Members: A Critical Aspect of Medical Care. Journal of the Royal Society of Medicine, 106(10), 399–407. https://doi.org/10.1177/0141076812472616
  3. LoBiondo, G., & Haber, J. (2018). Nonexperimental Designs. In: Nursing Research Methods and Critical Appraisal for Evidence-Based Practice (9th ed., pp. 184-185). St. Louis, MO: Elsevier.

Essay on Cancer Gene Therapy

Gene therapy is an experimental method for correcting faulty genes that cause disease to develop. Gene therapy attempts to treat illness by altering a person’s gene expression, with the ultimate goal of curing or preventing genetic diseases. Gene therapy aims to solve the problem at its source by inserting the right gene or repairing an existing one.

Genes are the fundamental components of all living species. Genes are in charge of producing proteins that enable cells to work properly. These proteins are also involved in cell division, and cancerous cells make extensive use of them. Gene therapy controls cell division cycles by manipulating the genes of the cells to improve or suppress protein functions. It changes the genetic material of cells, causing them to either return to their original state or to self-destruct.

Gene therapy can be carried out in a variety of ways. The three most popular forms of gene therapy are: 1) replacing a faulty gene with a healthy one, 2) modifying a gene to restore normal function, and 3) controlling the gene’s regulation.

Recent studies have come up with many gene therapies to treat cancer disease. They are described below:

  1. Oncolytic virotherapy: a form of gene therapy that targets cancer cells and kills them. A virus is injected into the patient as part of this procedure. The virus’s ability to damage normal cells has been reduced, while its desire to infect cancerous cells has increased. After being injected, the virus seeks out cancerous cells, infects them, and kills them.
  2. Apoptosis: by inducing apoptosis, gene therapy may cause cancerous cells to commit suicide. Apoptosis is induced using a variety of gene therapies, including lipid-based nanoparticles and tumor-suppressing genes. Experiments show that after being treated with these therapies, the number of tumor cells decreased by 70 to 80 percent within 48 hours.
  3. Suicide genes: this procedure entails implanting a patient with a gene that has been artificially altered. This gene has been tampered with so that it can detect cancerous cells inside the body. It injects itself into cancerous cells as it comes into contact with them. It self-destructs after being incorporated, causing the cancer cell to die. It’s known as a suicide gene because it kills itself to destroy cancer cells.
  4. Gene transfer: instead of destroying all of the cells, a process known as gene transfer allows cancerous cells to return to their original function. A gene is artificially inserted into the patient’s genome during gene transfer. These genes have been improved to have special properties that can help with cancer treatment. This approach replaces genes that cause rapid division with genes that allow them to regulate their division.
  5. Nanomagnetic technology: plays a vital role in cancer or tumor treatment. Magnetic forces between tumor cells and monocytes are used in this procedure. A nanomagnet is first implanted in a drug-carrying monocyte. The monocytes are injected into the bloodstream after another nanomagnet is placed next to the tumor. This technique has been very effective in targeting only cancerous cells while preventing normal cells from being harmed due to the presence of magnets, which produce a magnetic field and an enticing force for other magnets.
  6. Microenvironment: a type of gene therapy has been created that can establish a microenvironment around the tumor, preventing the cells from spreading. Since the infected cells can be differentiated from normal cells, this method makes it easier for clinicians to deal with the tumor.

As a result, gene therapy has surpassed chemotherapy as the most successful cancer treatment.

The Lung Cancer: Symptoms, Diagnosis, Causes And Treatment

Introduction

As a point of departure, to understand how a tumour appears in our lungs we have to know how is our lungs anatomy. As we all know, the lungs are two organs located in the thorax and they carry out the breathing. They are separated by an area called mediastinum, where the heart, trachea, esophagus and blood vessels are founded.

The air reaches the lungs through the trachea which is divided in tow principal bronchus, one on the right side and another on the left side, as the lungs.

But, how appears a tumour? Our organism is constituted by organs, which are made up by cells as a whole. These cells are regularly dividing in order to replace the aged or dead ones. This process is regulated by some mechanisms which indicate when the cells have to divide. If these mechanisms are modified in a cell, its descendants will start an uncontrolled division that will provoke a tumour or a nodule.

Moreover, these cells apart from growing without any control, they can move and proliferate in other parts of the organism, what is called metastasis, it is known as a malignant tumour.

In addition, when these malignant cells reach and implant in remote organs, such as the lungs, is when we talk about lung cancer.

Symptoms

In most cases, a malignant tumour in the lung is diagnosed when the cancer lung symptoms force the patient to go to the doctor. Due to the fact that the symptoms are late, the lung cancer is diagnosed in advanced stages.

The first symptoms are:

  • Cough: is the most common one of this type of cancer. It is produced by bronchial irritation and sometimes goes with expectoration. It is typical of tumours located in the central area of the lung.
  • Hemoptysis or bloody sputum: is the blood or bloody mucus expulsion from the respiratory tract. This is one of the most striking symptoms and thanks to it the patient goes to the doctor.
  • Chest pain: it is produced when the tumour affects the thoracic wall or the pleura. It is frequent of tumours located in the most circumferential area of the lungs.

Diagnosis

The first step for the lung cancer diagnosis is to make the medical history to the patient. Secondly, we need to look for signs or symptoms that may correspond to the illness doing a physical exam.

The most usual tests are:

  • Blood and urine test: they are the first ones to be made. It´s objective is to know about the patient´s overall health, if he or she has any renal or hepatic function alteration.
  • Chest radiography: this is an indispensable test in the lung cancer diagnosis. The nodules or patches onset in the lungs, mediastinum changes or pleural effusion are some suggestive signs of this illness.

Bronchoscopy or fiber bronchoscopy: it is used to inspect the trachea and bronchi from inside of them. It is realized through a pliant tube called bronchoscope in the respiratory tract. Inside of the tube there is fiber optic, which allows the specialist to see all the path from a TV monitor.

Prognosis and causes

The lung cancer was the cause of 1200000 deaths in the whole world in 2002, being the first cause of death in men and the second in women.

Lung cancer survival:

According to the last data published, a 10,7% of the patients who suffer from lung cancer, they survive more than 5 years. Together with the liver, pancreas and esophagus are the worst prognosed tumours due to the difficulty of realising an early diagnosis. The Spanish survival is similar to the European.

Lung cancer mortality:

18000 people die per year due to this disease in Spain, about 16000 man and 2000 women, which is the first cause of death for men and the sixth for women.

The Spanish mortality is higher than in the rest of the world, it is only overcome by the eastern countries in the male sex. For women, is one of the lowest in the world, but it is increasing since the 90s.

The death average age is 68 years in men and 66,6 in women.

There are many risk factors and possible causes of lung cancer. Some of the principal causes are: tobacco between the 80-90% of lung cancer cases take place in smokers. As a consequence, stop smoking reduces the risk of lung cancer appearance.

Moreover, the posibilities of developing lung cancer increases with the age and men have a rate three times higher than women. This is because women started to smoke from 30 to 40 years later. And finally, pollution, it is said that around 500000 deaths caused by lung cancer and 1,6 million deaths caused by COPD (chronic obstructive pulmonary disease) can be attributed to the air pollution.

Treatments and effects

The lung cancer treatment, as in the rest of tumours, is multidisciplinary. Many specialists work together to combine different therapies. The type of the treatment depends on the illness ‘stage, type of tumour (microlithic or non-microlithic) and the patient´s characteristics.

The most frequent treatments are

  • Surgery: is the first option and the most effective in non-microlithic cases. The type of surgery depends on the size, location and extension of the tumour. The non-microlithic surgery has complications and adverse effects. They aren´t usually a problem for the patient but they modify his or her quality of life.
  • Radiotherapy: this is the ionizing radiation employment for the local treatment of certain tumours, which use X-ray with high doses of radiation. It´s objective is to destroy the tumour cells causing the less damage to the healthy tissue around them. Some of the secondary effects that can appear are: exhaustion, skin reactions, hair loss…
  • Chemotherapy: antineoplastic and chemotherapy drugs are used in this technique. They reach to the majority of the tissues and there, they carry out its function over the health and malignant cells. Due to this fact, it produces secondary effects, such as hair loss, mouth sores, increasing of infections and exhaustion.

Conclusion

As I have already explained, the lung cancer isn´t a simple disease but it isn´t mortal if it is diagnosed early and the medical treatments are applied, which save thousands of lifes each year.

To be honest, we have made a huge progress finding new treatments but there is still a great deal to do. We have to do our best to reduce the disease numbers and to increase the scientific study budget in order to develop new cures and to improve the actual ones.

Bibliography

  1. Aecc.es (Internet). España: Madrid; Disponible en: https://www.aecc.es/es
  2. Medlineplus.gov (Internet). Rockville Pike, Bethesda;(actualizado 21 agosto 2019) Disponible en: https://medlineplus.gov/spanish/lungcancer.html
  3. Mayoclinic.org (Internet). Phoenix/Scottsdale; 13 Agosto 2019. Disponible en: https://www.mayoclinic.org/es-es/diseases-conditions/lung-cancer/diagnosis-treatment/drc-20374627
  4. Cancer.or (Internet).2019. Disponible en: https://www.cancer.org/es/cancer/cancer-de-pulmon.html

Immunotherapy in Head and Neck Cancer

Head-and-neck squamous cell malignant growths are one of the most well-known tumors worldwide and represent the greater part million new cases and 480,000 passing for each year. Major etiological hazard factor incorporates tobacco use, betel-quid and areca-nut biting, liquor utilization, human papillomavirus (HPV) contamination (oropharyngeal disease), and Epstein–Barr infection disease (nasopharyngeal cancer). An enormous number of patients are determined to have privately propelled ailment and require multimodal treatment approaches. Despite progresses in radiation and careful procedures and the utilization of chemotherapy and monoclonal antibodies in cutting edge ailment, most of all patients repeat remotely.

Tumor cells from different strong malignancies, including HNSCC, over-express PD-LI to habituate the safe checkpoint pathways to sidestep insusceptible surveillance. Pembrolizumab and nivolumab are PD-1 antibodies that intrude on the immunosuppressive pathway of inhibitory checkpoints, which are utilized by tumor cells to anticipate the carcinoma.

Mechanism Responsible for Carcinogenesis

Immune Evasion

Maintaining a strategic distance from insusceptible devastation is one of the signs of cancer. Tumors sidestep invulnerable reaction through various immunologic opposition systems: advancement of T-cell resistance, tweak of fiery and angiogenic cytokines, downregulation of antigen processing machinery (APM), and the outflow of safe checkpoint ligand end receptors. Tumor cells additionally build up a safe suppressive microenvironment by advancing the emission of immunosuppressive cytokines, for example, tumor growth factor-beta (TGFβ) and interleukin 10 (IL-10) which smother T-cell multiplication and cytotoxic capacity and downregulate articulation of co-stimulatory particles and MHC. These cytokines repress dendritic cell development, macrophage enactment, cytolysis by normal killer cells, and cytotoxic T lymphocytes. There are three kinds of immunosuppressive hematopoietic cells that are selected in the tumor microenvironment and assume a significant job in insusceptible getaway: myeloid-inferred silencer cells (MDSCs), tumor-related macrophages (TAMs), and administrative T-cells (Tregs). Penetrating MDSCs produce arginase-I to utilize L-arginine (which is a basic amino corrosive that is critical for the capacity of T-cells) to hose T-cell response.

HPV malignant growth is a key model for understanding tumor safe evasion. Although HPV disease is normal, HPV-related malignancy is very rare. Various investigations have demonstrated that HPV-contaminated cells effectively advance stromal irritation and collaborate with nearby microenvironment to advance oncogenesis. In HPV-related malignancy, there is a feeble T-cell reaction to HPV early antigens in blood alongside elevated levels of TILs that need cytotoxicity and expanded quantities of IL-10 creating tregs. HPV+ head-and-neck squamous cell cancers additionally has significant levels of T-invaded lymphocytes with high PD-1 articulation, and significant levels of PD-L1 articulation on tumor cells, and TAMs. These outcomes mean that a characteristic immunologic reaction is produced against HPV head-and-neck squamous cell cancers which incite PD-1/PD-L1 pivot and may confine the limit of TILs to come full circle an immunologic assault.

Immune Tolerance

Immune tolerance is characterized as inability to mount a resistant reaction to antigen. Tumor cells are heterogeneous with nonuniform articulation of tumor-related antigens and tumor-explicit antigens (TSAs). Head and neck cancer cells with elevated levels of tumor-explicit antigens are bound to be recognized by the safe framework and wiped out when contrasted with head-and-neck squamous cell cancers cells with no or low degrees of tumor-explicit antigens which display low immunogenicity and break from resistant surveillance. The interchange between tumor antigen and TA-explicit is important for cytotoxic T-lymphocytes acknowledgment and tumor cell pulverization. Antigen processing machinery segments work pair to produce antigenic peptides, translocate into endoplasmic reticulum, load MHC Class I H chain with peptides, lastly transport MHC Class I particles to the cell surface to display the peptide to T-lymphocytes. Tumor cells can possibly diminish T-cell-interceded acknowledgment by downregulating or changing HLA I atoms or potentially antigen processing machinery segments to constrict antigen introduction.

Disruption of T-Cell Regulation

T-cell receptors associate with co-invigorating ligands and co-stimulatory receptors to give T-cell signal acknowledgment. Malignant growth cells repress T-cell-interceded acknowledgment and initiation by downregulating MHC I antigen introduction to endogenous T-cell receptors and furthermore through the inhibitory co-stimulatory receptor pathways. Two of the most usually included checkpoint inhibitory components are CTLA-4 and PD-1/PD-L1, which act at prior and later phases of insusceptible reaction to tumors. CTLA-4 rivals CD28 receptor, an initiating co-stimulatory receptor, for authoritative to B7 ligand (CD80 and CD86) found on APCs, bringing about T-cell inactivation. In ordinary cells, PD-1 ties to its ligands PD-L1/PD-L2 to lessen T-cell effector movement and end invulnerable reaction. In any case, PD-L1 is overexpressed in most of tumors, and this resistant brake signal is embraced by cells to avoid invulnerable elimination.

Different Types of Immunotherapy in Head and Neck Cancer

Checkpoint Inhibitor

Allison made a major leap forward in the field of invulnerable oncology by setting up another idea that, aside from antigen introduction, enactment of cytotoxic T-cells required an optional costimulatory sign to accomplish antitumor invulnerability. The revelation of inhibitory pathways, which stifle T-cell movement prompting tumor development, made a major transformation in the field of immunotherapy. Obstructing these inhibitory pathways by means of monoclonal antibodies, which are generally called checkpoint inhibitors, has demonstrated to be probably the most ideal approaches to relapse tumor.

Checkpoint hindrance has an assortment of utilizations in resistant oncology running from lung malignant growth to oral cancer. Among checkpoint inhibitors, hostile to CTLA-4 and against PD-1 antibodies are generally utilized for helpful purposes. Hostile to CTLA-4 antibodies have more extensive T-cell work contrasted with against PD-1 antibodies, which reestablishes that enemy of CTLA-4 has more reactions than hostile to PD-1. As of late, against PD-L1 ligand is in the late period of business improvement for clinical practice with name durvalumab. Ipilimumab was endorsed by the European Organization for Research and Treatment of Cancer (EORTC) for the adjuvant treatment in patients with high-chance melanoma. The blend of nivolumab and ipilimumab was affirmed in the United States for the treatment of BRAF-negative melanoma. Apart from hostile to PD-1 and against CTLA-4 antibodies, other checkpoint inhibitor receptors, for example, lymphocyte-activation gene 3 (LAG3), mucin domain3 (TIM-3), and T-cell immunoglobulin have shown restorative impacts in clinical preliminaries in mix with PD-1 agents. The mix of radiation and PD-1 barricade was demonstrated to be synergistic in the treatment of cancer.

Targeted Monoclonal Bodies

Monoclonal antibodies are produced using either human or murine neutralizer parts that bound to tumor-related antigen prompting ADCC. The best model in this gathering which is utilized remedially is counter acting agent against epidermal growth factor. Deregulation of epidermal growth factor prompts the restraint of apoptosis, intrusion, metastasis, and angiogenic potential. Compared to typical mucosa, epidermal growth factor level is expanded in 95% of head-and-neck squamous cell cancers. In head-and-neck squamous cell cancers, the statement of epidermal growth factor is expanded, which corresponds with hostility of the malignancy. EGFR is answerable for tumor movement in numerous strong tumors, particularly in head-and-neck squamous cell cancers. Monoclonal antibodies, for example, cetuximab and panitumumab are epidermal growth factor focused on treatments; they are demonstrated to be successful against either alone or in blend with radiotherapy.

Adoptive Immunization

The significance of T-cells in the end of malignant growth cells is a settled marvel. Lymphocytes from tumor test or blood of the patient are collected, extended, and reintroduced for antitumor immunity. The viability of T-cells can be emphasized by bringing explicit antigen receptor into the cells by hereditary building, consequently upgrading their capacity to perceive tumor antigen. Encouraging outcomes were found in 93 patients treated for metastatic melanoma utilizing adoptive cell transfer. This procedure has demonstrated excellent to treat metastatic strong tumors, which are generally hard to treat with customary strategies. adoptive cell transfer with human papillomavirus – directed tumor-penetrating T-cells has indicated promising outcomes in patients with cervical cancer. Improvements in adoptive cell transfer are picking up force as a result of its prosperity rate; presentation of explicit antigen receptor into T-cells will slaughter disease cells specifically. Large-scale generation for clinical utilization of adoptive cell transfer is endeavored by building antigen receptors: one strategy is through complemented introduction of significant histocompatibility complex and the other is through chimeric antigen receptor.

Cytokine Immunotherapy

Cytokines are sub-atomic delivery system that permit the cells of our resistant framework to speak with one another to create an organized reaction to an objective antigen (disease cell). This immunotherapy animates insusceptible cells through a convoluted pathway, in this way expanding coordination between tumor cells and stromal cells. As of late, various cytokines have been created for the treatment of malignant growth. Two cytokines as of now affirmed by the FDA for clinical reasons for existing are interferon α (IFN α) and interleukin 2 (IL-2).

  • IFN α: these cytokines when infused subcutaneously in renal cell carcinoma have demonstrated tumor relapse. These have demonstrated magnificent outcomes in organize 3 melanoma. The blend of IFN α and IL-2 indicated fractional reaction and higher toxicity.
  • IL-2: It is an FDA-endorsed cytokine for metastatic melanoma. These cytokines increment level of Natural Killer cells and tumor-infiltrating lymphocytes (TILs) in the lesion. Perilymphatic IL-2 organization has expanded the endurance pace of patients with head-and-neck squamous cell cancers expanded tumor receptive T-cells were found in patients who experienced monoclonal counter acting agent treatment after surgery.

Conclusion

Cancer treatment is one of the difficult perspectives in the treatment modalities extending from medical procedure to chemotherapy and radiation are yielding blended outcomes. To defeat this obstacle, more up to date imaginative methodologies are expected to lessen the dreariness and mortality of the patients. The weaknesses of medical procedure, for example, repeat of tumor or inoperable injury and poisonous quality of radiotherapy or chemotherapy can be significantly diminished by immunotherapy when utilized in blend with these treatment modalities. Principle issues with immunotherapy is the absence of strong prescient markers of viability, particularly when the expenses of these medications are considered. It is still ongoing test for the treatment of head and neck cancer.

Immunotherapy for the Treatment of Cancer

As is well known, a singular treatment is not enough to eradicate cancer from the body. The older approach to treating cancer is with the use of chemotherapy, a nonspecific cytotoxic chemical, while the newer approach is to treat cancer with targeted and immunotherapy treatments which have the capability of specificity (Vanneman, Mathew, et al.). Chemotherapy kills all cells that produce rapidly, it is narrow spectrum, highly toxic, and resistance is known to occur quite frequently (Vanneman, Mathew, et al.). Because chemotherapy kills all highly prolific cells, this means that healthy cells are killed along with the cancerous cells. Chemotherapy, along with other conventional therapy methods, attack tumors and cancerous cells directly, while targeted therapy and immunotherapy do so indirectly (Rangel-Sosa, Martha, et al.). Targeted therapy blocks molecular pathways responsible for tumor growth and stability, and immunotherapy elicits an immune response and creates long term destruction of tumor cells (Vanneman, Mathew, et al.). One specific pathway targeted therapy block is oncogene addiction, which is “a process by which a single mutated gene or signaling pathway drives tumor proliferation” (Vanneman, Mathew, et al.). Targeted therapy also inhibits critical biochemical pathways and mutated proteins that stimulate tumor development, growth, and survivals; drugs have been used and prohibited disease development and increased regression in some cases (Vanneman, Mathew, et al.). In most cases, targeted therapy remission results are not permanent, just like with traditional chemotherapy. Since targeted therapy arrests tumor development and decreases a tumor’s suppression of the immune system, this provides an opportunity to utilize immunotherapy as well to create a greater cytotoxic effect against cancer cells. Combining treatment methods has been found to be helpful due to the diverseness of cancers, acquired resistance to medications, and the importance of individualized therapy. Combination is most efficient when each treatment is researched on how they interact with the immune system and what phase they begin working. Immunotherapy agents, radiation and chemotherapy dosage/type/duration, and any other therapeutic agents must work in synergy with each other and induce cohesive effects that play off of one another. For example, a combine therapy could include a suicide gene releasing tumor associated antigens that then recruit antigen presenting cells and T-regulatory cells. An immune checkpoint inhibitor could then suppress the T-regulatory cell activity and increase T-cell production. The T-cells produced and activated could then fight the tumor and create immune memory that would produce long-term tumor-lytic effects.

One study chose to look at rice bran arabinoxylan compound (RBAC) as an immunotherapy agent, and study its effects on cancer and the immune system when used in combination with chemotherapy. RBAC was found to be efficient at activating natural killer cell activity and eradicating cancer cells in-vitro and in-vivo (Jurasunas, Serge).

RBAC is a nutritional additive, made by the enzymatic hydrolysis of hemicellulose B (a dietary fiber found in rice bran) (Jurasunas, Serge). Arabinoxylan is a highly complex sugar that is obtained by extraction from bran rice; the extraction process breaks down the long polysaccharide molecule into smaller, less complex ones (Jurasunas, Serge). Arabinoxylan in its normal form is far too complex for absorption, when it is broken down into simpler molecules it can be absorbed into the circulatory system and spread throughout the body. RBAC is the most robust biological response modifier because it is a risk-free compound with no toxic qualities, that does not lead to an immunotolerance (Jurasunas, Serge). The main purpose of this supplemental treatment was to affect the activity of natural killer cells. Natural killer cells are large granular lymphocytes and they are the first line of defense from foreign substances, and as we know now, cancer as well (Jurasunas, Serge). This is especially important for cancer patients because this study found that individuals with cancer have 50% to 70% less natural killer cell activity and number than normal individuals (Jurasunas, Serge). Natural killer cells also decrease in affinity and in number with age, this could possibly be a reason that cancer rates increase with age. It also means that the natural killer cells that elderly cancer patients to have left are not functioning at full capacity. So, essentially, the idea behind this study was that if they could increase the number and activity of natural killer cells, the immune system would be more effective at killing cancer cells. Natural killer cells play an important role in innate immunity, but they also bridge the gap between innate and adaptive immunity as well. Natural killer cells have activating and inhibitory receptors within their cell membrane that allow them to be activated by any antigen or foreign material without any prior sensitization, and they have the ability to amplify tumor-lytic responses (Jurasunas, Serge). This is why natural killer cells are said to provide an upper hand in the prevention and treatment of cancer. Natural killer cells differentiate and mature in bone marrow, lymph nodes, the spleen, tonsils, and the thymus; after maturation the enter circulation (Jurasunas, Serge). When at rest, natural killer cells monitor the circulatory and lymph systems, and when a foreign entity (a cancer cell in this case) is discovered, they exhibit cytotoxic qualities and attack the cell (Jurasunas, Serge). The first way that they attempt to kill cancer cells is by the release of cytotoxic granules in response to cytokines (Jurasunas, Serge). When a cancerous cell is found, the natural killer cell adheres itself to the surface of the cell via receptors, it then injects granules of perforin and releases granzyme serine protease; this causes apoptosis of the cancer cell due to DNA degradation (Jurasunas, Serge). Perforin is a membrane disrupting protein that opens up the cancer cell membrane, forming an opening that allows the protease to enter the cell (Jurasunas, Serge). After activation, and the initial ‘attack’, natural killer cells can induce apoptosis within the cancer cell in as little as five minutes, and the process can be repeated for approximately twenty-seven times before the immune cell becomes permanently inactive (Jurasunas, Serge). Natural killer cells in normal cancer patients are degranulated and deactivated, while natural killer cells in patients supplemented with RBAC show increased granular content and increased adhesion capability (Jurasunas, Serge). The study found that RBAC creates cell recognition through supplement immunoprofile, decreases antigen tumor markers, improves treatment, and increases lifespan compared to patients receiving chemotherapy only (Jurasunas, Serge). While natural killer cell activity after RBAC supplementation alone increases initially, reaches a plateau, and then slowly declines, the study found that the use of RBAC coupled with conventional treatment (such as chemotherapy) found the cause less recurrence, decreased mortality rate, and an overall improvement in quality of life after treatment (Jurasunas, Serge). In another study of cancer patients receiving RBAC supplementation along with chemotherapy, natural killer cell activity rose and the increased activity continued even after supplementation stopped; the immune activity was maintained for approximately five years (Jurasunas, Serge). Overall, RBAC has shown the potential to: increase efficiency of conventional cancer treatment, reduce tumor size, decrease metastatic lesions, decrease tumor markers, minimize adverse side effects, and increase the chance of extended remission when coupled with traditional treatment (Jurasunas, Serge). This seems like a medical revelation. Why is this practice not utilized in every single cancer case?

Cancer is the second leading cause of death in the United States. Metastatic lung cancer is the first leading cancer in mortality rate, and metastatic prostate cancer is the second (Janiczek, Marlena, et al.). Immunotherapy is specifically useful in treating metastatic conditions, but the hope is that certain immunological agents can be tailored to treat early and non-metastatic cases as well. This could potentially prevent the spread of the cancer before it is too late. One study took the unit cost of each immunological agent and its dosage to find the cost per treatment, and then took the cost per treatment times the treatment length to find the cost over time, by cancer type, for each immunotherapy treatment (Shih, Ya-Chen, et al.). Trastuzumab was found to cost $50,000 yearly, bevacizumab came out to be around $10,000 every eight weeks, and cetuximab cost $20,000 every eight weeks (Shih, Ya-Chen, et al.). Bevacizumab in combination with FULFIRI showed increased responsivity (from 35% to 45%) and increased the average survival rate by almost five months (Shih, Ya-Chen, et al.). Trastuzumab when coupled with chemotherapy showed to be 50% responsive, increased survival rate by five months, decreased the chance of remission, and reduced the death rate by more than half (Shih, Ya-Chen, et al.). As stated before, immunotherapy is an incredibly useful took in the fight against cancer, but it comes at a hefty cost. In 2004 it was predicted that immunotherapy treatments would increase the cost of treating cancer by more than 370 million dollars.

This is worth mentioning because the United States is an aging population, meaning the general population is living longer and there are more elderly individuals than there are younger individuals. Because of the fact that as you age the likelihood of getting cancer increases, if there are more elderly individuals within a population there will be more instances of cancer. More instances of cancer therefore result in an exponential increase in healthcare costs. Immunotherapy has proven itself as a treatment for cancer, but with it being the newest treatment available, the cost is still high. It is important as a society for these treatments to be available across the board. Underprivileged and/or those without health insurance are not likely to benefit from this treatment based on the costs associated with administration.

Immunotherapy is a game changer in the field of medicine in regards to cancer treatment. Further research could unlock the answer to a cure. If scientists can figure out how to recruit the immune system to aid in the attack of cancer cells, maybe they could figure out a way to get the immune system to completely eradicate the disease on its own. Chemotherapy and radiation are very toxic, and in most cases seem to be counterproductive. The purpose of chemotherapy and radiation is to kill off cancer cells, and while they do accomplish that goal, they also kill off large quantities of healthy cells. The trick with such treatments is to find the type and dosage that kills all of the cancer cells before it kills the patient. These treatments also cause extremely adverse side effects, such as fatigue, hair loss, nausea, bruising and bleeding, increased risk of infection, loss of appetite, weight loss, mood and behavioral changes, and nerve and muscle damage (Hadish, Cindy). While immunotherapy still comes with its fair share of risks and side effects, the flu-like symptoms involved do not compare to that of chemotherapy (Hadish, Cindy).

In conclusion, immunotherapy has already shown great promise as a cancer treatment, but with further research we can explore even more options (possible even a cure) and attempt to make it available to all demographics that are in need of treatment.

Oral Cancer as One of the Most Popular Types of Cancer

Oral cancer is known as one of the most popular types of cancer among people all over the globe, and there are about 200K deaths recorded annually, as a result of it. Oral cancer occurs when a bunch of malignant cells infect the oral tissues, and this harms the oral cavity overall, including different parts, such that the lips, gum, palate, and tongue. It mainly happens as a result of carelessness when it comes to dental care. There are various symptoms that could indicate the presence of oral cancer, for instance, the inability of swallowing food, lip or mouth inflammation, loosened teeth, mouth bleeding, and others.

There are several causes for oral cancer, indeed, but the over-consumption of alcohol could be one of the main reasons. Moreover, combining both, smoking cigarettes, and drinking alcohol in big amounts, is surly more effective than doing one of these habits all alone. Based on researches, 3 out of 4 people who drink and smoke, simultaneously, are mostly affected by oral cancer more than others, because the ingestion of alcohol dehydrates the cell walls, which would make them absorb the tobacco carcinogens even more and facilitate its entrance to the mouth tissues smoothly. It could also damage the natural resistance ability of the antibodies to prevent the formation of cancel cells or to fight against them, and against any other disease as well. Reducing the intake of both, tobacco and alcohol, would definitely have a significant positive effect in reducing the possibility of being infected with oral cancer, nonetheless, the risk of being infected should be as minimal as those who neither smoke, nor drink, in the up-coming 10 years.

Experts, such as the UT Southwestern Medical Center’s oral surgeons, have stated some scientific evidence that strengthens these ideas. The cirrhosis of the liver, as a result of the consumption of alcohol, could be associated with oral cancer as well, based on some researches. Those who suffer cirrhosis mainly develop a shiny, smooth oral mucosa’s appearance (in both of the throat and the mouth’s tissues), due to liver-induced changes in the cells. Such cases and the actual reason behind the presence of this isn’t fully understandable, yet, so that more researches and investigations are being done.

There are also some several kinds of tobacco which are smokeless, pan, which are pieces of areca nut, and slaked lime, are enclosed in a piper betel vine leaf. The pan, and all forms of the smokeless tobacco contain substances which is capable of causing cancer in living tissues. Past researches assure that the micronuclei cells are notably larger in quantity in smokeless tobacco users, in-compare to normal smokers. The buccal mucosa, gingiva and buccal sulcus are in high risk to get affected because of the placement of tobacco liquids, such as khaini, gutkha, and betel quid, in the oral cavity. Also, one more cause of oral cancer that the majority of people aren’t aware of, is the direct exposure to the sun while sun-bathing, and using lip-balms or creams could definitely reduce the risk of getting oral cancer out of it. Also, wearing a head-piece, such as caps, could block the harmful ultraviolet rays.

The treatment for such a type of cancer usually depends on its stage, and the overall health of the patient and their will. One can under-go for just one kind of treatment or a combination of cancer treatments that include chemo and radio therapy, along with the surgeries and each type of them classifies. As an example, if a patient decides to under-go a surgery, the surgeon must check-up whether the cancer cells have spread towards the neck or not. He might cut away the tumor and a part of the uninfected tissues around that area to make sure that all the cancer cells are well-removed. However, in-case of larger tumors, a part of the patient’s jawbone, or a part of their tongues should be removed.

If the cancer cells have spread to the neck, and to the lymph-nodes specifically, the patient would be advised to go through a surgery to remove lymph nodes and the tissues that might’ve been infected, as well, and they might also need some kind of treatment after the surgery. It’s also known that it takes a long period to heal from such, and a re-construct surgery for the mouth could be done, to be able to talk and eat normally, again. Yet, treatments that the patents might go for, could also have some side-effects, which could mainly be the destruction of healthy cells and tissues, but this mostly depends on the location, the type, and the stage of the tumor. The routine of visiting the dr for a radiation session or whatever the treatment is, is really hard for the patients and their families, which could also cause some psychological issues, such as mood swings, irritability, phobias, insomnia, depression, and the list goes on.

On the other hand, the five-year survival rates are getting more advanced and getting better. Between the 1975-1977 the survivals percentage were 49, but is rose to 68 percent in the interval 2002-2008.

There are many ways that one could do to avoid mouth caner or eliminate the risk of getting it. One should brush his teeth regularly, and after having any meal, floss their teeth every day, visit their dentists regularly, and avoid alcohol and tobacco as much as they can. Governments should also create some strict rules to ban the over-consumption of tobacco and alcohol, as they’re the main source of mouth cancer. Raising awareness about this type of cancer would make people more aware about how much they’re harming themselves and other around them, and they should know that the immediate consultation matters and has a significant effect of getting rid of the tumor in some really early stages, and increases the survival rate.

Impact of Exercise on Cancer Mortality for Adults

Cancer is a disease associated with the growth of abnormal cells that divide uncontrollably and destroy normal body tissue. Skinner et al. (2005) cancer is not a single disease but rather a term that defines the uncontrolled spread of cells. Furthermore, a study by Dennis J. Kerrigan et al. (2013) found cancer is one of the leading causes of morbidity and mortality throughout the world. Two in one people in the world will be diagnosed with cancer, this is a significant problem. The main points that the study will investigate are the problems that cause cancer to happen, explain the pathophysiological of cancer and how exercise can have an impact on cancer. The study aims to provide evidence-based exercise prescription to cancer patients.

The effects of cancer on physical functioning depends on the stage and type of cancer and the results of treatment. A study by Skinner et al. (2005) found local disease has a small chance of impacting cancer patient day to day activities. However, a study by Adrianne E. Hardman et al. (2009) found, some patients are not limited physically until their disease has progressed to an advanced stage. The difference, patients whose presenting symptom is pain may be limited early with cancer. Andrew Scott et al. (2016) found the most common treatments for cancer are surgery, chemotherapy and radiation therapy. Additionally, a study by Skinner et al. (2005) found surgery can have both minor and vital effects on a patient. This can result in decreased strength, endurance, and range of motion of the affected limb. Andrew Scott et al. (2016) found common effects of chemotherapy can result in fatigue, nausea, vomiting, insomnia, weight gain, and anemia. Furthermore, the same study by Andrew Scott et al. (2016) found radiation therapy can result in fatigue and the possible scar tissue formation in the exposed area. The difficulty of fatigue limits physical activity in a huge portion of cancer patients. The results of the study showed how important rest is for patients to recover, however, long term rest can have a major impact on the reduction of physical activity which can lead to several more problems. A study by Skinner et al. (2005) found patients who have finished treatment for cancer will experience a decrease in lean body mass, aerobic fitness, muscular strength, muscular endurance and affect their flexibility and this will result in a massive increase in body fat. The decrease in overall physical fitness could have a huge impact on the ability of a cancer patient to carry out daily activities.

Each year, approximately 14.1 million new cases of cancer are diagnosed worldwide. In the United Kingdom, more than one in three people will develop cancer at some time during their lifetime, and the latest UK statistics show that more than 331,000 people were diagnosed with cancer in 2011. However, Cancer Research UK (2020) states that one in two people will develop cancer at some point in their lives. Cancer is most common with old age, a study by Andrew Scott et al. (2016, p.103) states that cancer is more common in later life, with 53 percent of cases diagnosed in people aged fifty to seventy-four years and 36 percent after age seventy-five years. However, in Cancer Research UK (2014) found detection systems are improving and more effective treatment options are available, leading to cancer deaths to decrease by 10 percent in the last decade and resulting in half of the patients living longer up to ten years more. Additionally, a study by Dennis J. Kerrigan et al. (2013) found the estimated prevalence, the number of people alive following a cancer diagnosis is currently 3 percent and this represents about two million people. However, a study by Maddams et al. (2012) found since UK population is aging, cancer prevalence is projected to increase by 55 percent in males compared to 35 percent of females in the next two decades, this will result in more than four million people living with cancer by 2030 (Mistry et al. (2011).

Jonathan K. Ehrman et al. (2018) found the normal growth and proliferation of cells within the body is under genetic control. The stem cell theory is the model developed to describe the orderly proliferation of cells, specialization to perform to perform discrete functions and cell death within an organ. Additionally, the study by Jonathan K. Ehrman et al. (2018) studied the stem cell is pluripotent, which meant that it is an uncertain cell with many developmental options still open. The process by which the stem cell is capable of producing special functions within an organ system. However, study by Dennis J. Kerrigan et al. (2013) found some stem cells are activated to transform into hair cells and some cells become cardiac myocytes. The pluripotent stem cell has the volume for self-renewal. Andrew Scott et al. (2016) found that after a stem cell commits to a cell line for instance a hair cell it will no longer will have pluripotent and self-renewed properties and is destined to grow along its specialized pathway of diversity. A great example is a pluripotent hematopoietic stem cell. A study by Jonathan K. Ehrman et al. (2018, p. 380) states that the best example is a pluripotent hematopoietic stem cell, with its capacity to form both red and white blood cells. After it commits to a specific cell line, it can no longer differentiate into other cell types or divide into new cell forms (Jonathan K. Ehrman et al. 2018).

In one early RCT, seventy inpatients with solid tumors receiving high dose chemotherapy followed by stem cell transplantation were allocated to daily exercise on a supine cycle ergometer or to usual care (Dimeo et al., 1997). At discharge, exercisers recorded a significantly smaller decline in physical performance (14 percent) than controls (19 percent), and had been hospitalized for one and a half fewer days. Several treatment related complications were lower among the exercise group, including pain, diarrhea, thrombopenia, and neutropenia. A systematic review of eight RCT’s of exercise interventions for cancer patients undergoing hematopoietic stem cell transplants reported some encouraging results (Wiskemann and Huber, 2008). Exercising during impatient says helped to prevent aerobic and muscular deconditioning, enhance quality of life, and improve immune function. Exercise after discharge led to improvements in aerobic and muscular functioning, quality of life, and body composition.

A comprehensive systematic controlled review published in 2010 summarized all randomized and non-randomized controlled trials involving exercise interventions for cancer populations (Speck et al., 2010). Based on thirty-three trails involving exercise performed during treatment (usually chemotherapy or radiotherapy). Significant small to moderate beneficial effects were evident for aerobic fitness, muscular strength, body fat percentage, and anxiety. Subsequently, another systematic review focused on quality of life outcomes from trails of exercise performed during cancer treatment (Mishra et al., 2012). Collectively, the results from fifty-six RCT or quasi randomized trails indicated an overall small improvement in global quality of life after exercise interventions, compared with control conditions.

The benefits achievable through exercise are not limited to patients with good prognoses. Several systematic reviews of a small, but growing, body of evidence have concluded that exercise interventions may help maintain, or slow the decline in, quality of life and fatigue among patients with advanced cancer (Lowe et al., 2009). A study by Albrecht and Taylor, (2012) found the strongest evidence has come from a large RCT involving 231 patients with incurable disease and short life expectancy (Oldervoll et al., 2011), comparing the effects of an eight-week supervised group exercise intervention with usual care. Unsurprisingly, given the population, the number of patients not completing the trail was high. Nonetheless, encouraging results were reported, with significant increases in physical function outcomes grip strength and walking performance observed for the exercise group. These improvements can be very important for enabling performance of activities of daily living.

In 2010, the American college of sports medicine convened a multidisciplinary expert panel to provide guidelines on exercise for cancer survivors (Schmitz et al., 2010). The panel concluded that exercise is safe and effective during and after cancer treatment. The review concentrated on breast, colon, prostate, gynecological, and hematological cancers and provided cancer specific screening criteria for starting and stopping an exercise program. For instance, they recommend that a colon cancer patient with an ostomy should receive permission from a health professional before participating in exercising. Likewise, if a woman with breast cancer reported swelling in the arm or hand during exercise, it is recommended that upper body exercise should be minimized until appropriate medical evaluation and action took place. A set of guidelines relating to safety considerations for cancer survivors have been published in the ACSM’s guidelines for exercise testing and prescription (Pescatello et al., 2014).

Additionally, a study by Andrew Scott et al. (2016) found the common side effects of cancer treatments include nausea, vomiting, anorexia, altered taste and smell that may lead to reduced nutrient intake. Specialist oncology dieticians can provide individualized guidance to patients in developing suitable diet plans. The general aims are to prevent or correct nutritional deficiencies, achieve or maintain a healthy body weight, preserve lean mass and prevent fat gain. For patients after treatment result in specific long-term alterations to dietary intake. For all patients after treatment completion, dietary advice is aimed at avoiding excess weight gain, and minimizing food associated with increased risk of recurrence. An evidence-based report from the World Cancer Research Fund provided a series of dietary recommendations with regard to preventing cancer that were directed to people with a cancer diagnosis (World Cancer Research Fund, 2007). These included limiting consumption of energy dense foods, avoiding sugary drinks, eating mostly foods of plant origin, e.g., vegetables, fruit, limiting red meat and limiting alcoholic drinks, limiting salt, and avoiding dietary supplements unless prescribed by expert.

To get a cancer patient starting exercise in an exercise program. When in doubt when and where to start, I would use the 50% rule; ask the patient how far can they walk before becoming too tired. And start at half that distance time. The exercise program for cancer patients does not typically involve electrocardiographic monitoring, although some supervision and instruction about heart rate monitoring, proper exercise techniques and cancer specific exercises should be included. The exercise prescription should be reviewed with the patient and the cancer patient should be instructed about proper intensity (RPE scale) and recognizing common adverse symptoms to exercise. Related to current exercise for healthy adults, I will encourage the cancer patients to participate in general (total body) resistance as well as flexibility exercises. Furthermore, prescribing exercise during active treatment should give attention to specific treatment side effects and, when possible, an oncologist should be consulted regarding limitations. Patients with cancer, set backs are common and interruptions are also not uncommon. Instead of not making the patient stop the exercise programs and allow the patients to plan around setbacks and continue to follow to the program when they can.

Cancer is characterized by uncontrollable reproduction of abnormal cells in any part of the body. It can begin in any organ and spread to other organ systems. Cancer is a major cause of morbidity and mortality. Over half of cancer deaths are accounted for by cancer of the lung, breast but the risk factors vary by tumor site. The most common treatments for cancer are surgery, chemotherapy, radiation and hormonal therapy. Both the disease and treatment bring emotional and physical challenges to patients with cancer. Exercise benefits these patients primarily through improving function, reducing fatigue and countering some of the side effects of cancer therapy.

Bibliography

  1. Albrecht, T.A. and Taylor, A.G., 2012. Physical Activity in Patients with Advanced-Stage Cancer: A Systematic Review of the Literature. Clinical journal of oncology nursing, 16(3), p.293.
  2. Cancer Research UK. 2020. Bowel Cancer Statistics. [online].
  3. Dimeo, F., Fetscher, S., Lange, W., Mertelsmann, R. and Keul, J., 1997. Effects of Aerobic Exercise on the Physical Performance and Incidence of Treatment-Related Complications After High-Dose Chemotherapy. Blood. The Journal of the American Society of Hematology, 90(9), pp.3390-3394.
  4. Hardman, A.E. and Stensel, D.J., 2009. Physical Activity and Health: The Evidence Explained. Routledge. https://www.sciencedaily.com/releases/2015/02/150203204348.htm [Accessed 21 Feb. 2020].
  5. Kerrigan, D.J., Williams, C.T., Ehrman, J.K., Saval, M.A., Bronsteen, K., Schairer, J.R., Swaffer, M., Brawner, C.A., Lanfear, D.E., Selektor, Y. and Velez, M., 2014. Cardiac Rehabilitation Improves Functional Capacity and Patient-Reported Health Status in Patients with Continuous-Flow Left Ventricular Assist Devices: The Rehab-VAD Randomized Controlled Trial. JACC: Heart Failure, 2(6), pp.653-659.
  6. Lowe, J.A., Huntingford, C., Raper, S.C.B., Jones, C.D., Liddicoat, S.K. and Gohar, L.K., 2009. How Difficult Is It to Recover from Dangerous Levels of Global Warming?. Environmental Research Letters, 4(1), p.014012.
  7. Maddams, J., Utley, M. and Møller, H., 2012. Projections of Cancer Prevalence in the United Kingdom, 2010–2040. British journal of cancer, 107(7), pp.1195-1202.
  8. Mishra, S.I., Scherer, R.W., Snyder, C., Geigle, P.M., Berlanstein, D.R. and Topaloglu, O., 2012. Exercise Interventions on Health‐Related Quality of Life for People with Cancer During Active Treatment. Cochrane Database of Systematic Reviews, (8).
  9. Oldervoll, L.M., Loge, J.H., Lydersen, S., Paltiel, H., Asp, M.B., Nygaard, U.V., Oredalen, E., Frantzen, T.L., Lesteberg, I., Amundsen, L. and Hjermstad, M.J., 2011. Physical Exercise for Cancer Patients with Advanced Disease: A Randomized Controlled Trial. The oncologist, 16(11), p.1649.
  10. Pescatello, L.S., Riebe, D. and Thompson, P.D. eds., 2014. ACSM’s Guidelines for Exercise Testing and Prescription. Lippincott Williams & Wilkins.
  11. Schmitz, K.H., Courneya, K.S., Matthews, C., Demark-Wahnefried, W., Galvão, D.A., Pinto, B.M., Irwin, M.L., Wolin, K.Y., Segal, R.J., Lucia, A. and Schneider, C.M., 2010. American College of Sports Medicine Roundtable on Exercise Guidelines for Cancer Survivors. Medicine & Science in Sports & Exercise, 42(7), pp.1409-1426.
  12. ScienceDaily. (2020). One in Two People in the UK Will Get Cancer, Experts Forecast. [online].
  13. Skinner, J.S. ed., 2005. Exercise Testing and Exercise Prescription for Special Cases: Theoretical Basis and Clinical Application. Lippincott Williams & Wilkins.
  14. Speck, R.M., Courneya, K.S., Mâsse, L.C., Duval, S. and Schmitz, K.H., 2010. An Update of Controlled Physical Activity Trials in Cancer Survivors: A Systematic Review and Meta-Analysis. Journal of Cancer Survivorship, 4(2), pp.87-100.
  15. Wiskemann, J. and Huber, G., 2008. Physical Exercise as Adjuvant Therapy for Patients Undergoing Hematopoietic Stem Cell Transplantation. Bone marrow transplantation, 41(4), pp.321-329.
  16. Yoon, G.H., Stein, J.P. and Skinner, D.G., 2005, May. Retroperitoneal Lymph Node Dissection in the Treatment of Low-Stage Nonseminomatous Germ Cell Tumors of the Testicle: An Update. In Urologic Oncology: Seminars and Original Investigations (Vol. 23, No. 3, pp. 168-177). Elsevier.

Impact of Stress on the Progression and Recurrence of Cancer

Cancer consists of a large number of diseases where cells from a specific part of the body grow and reproduce uncontrollably, which end up infiltrating and destroying normal body tissue (MayoClinic, 2020). This uncontrollable growth and reproduction occur as a result of interference of the normal genetic process involved with cell growth and reproduction (Conquer Cancer: ASCO, 2020).

Each individual gene contains DNA which, in turn, contains a set of instructions on the functions of growth and reproduction of the cell. Errors in the instructions within the DNA can cause cells to stop its normal function and as a result, the cells start to divide and grow uncontrollably forming a mass called a tumour (MayoClinic, 2020). These genetic mutations can either instruct the cell to divide more rapidly than necessary; stop the cell from knowing when to stop growing and thus, grow rapidly; or make mistakes when fixing DNA errors, thus causing it to become cancerous (MayoClinic, 2020).

The cause of cancer is attributed to an interaction between genetic, environmental, and constitutional characteristics around an individual (Stanford Health Care, 2020). These characteristics tend to be ‘activated’ due to repeated exposure to risk factors, which may not necessarily cause the cancer, but increase the chances of getting cancer (Conquer Cancer: ASCO, 2020). Some of these include genetics, age, lifestyle choices, existing medical conditions, and exposure to certain carcinogens in one’s environment (Stanford Health Care, 2020). While some risk factors such as genetics and age are uncontrollable, others such as lifestyle choices and exposure to carcinogens can be manipulated to reduce as much risk as possible.

Cancer is classified into different types based on the origin of the growth: carcinoma, sarcoma, mylenoma, leukemia, and lymphoma. Carcinomas begin in the skin or tissues that line the internal organs, and account for 80 to 90 percent of all cancer cases (National Cancer Institute, n.d.). Sarcomas develop in the supportive and connective tissues such bones, cartilage, fat, muscle or other connective tissues (Conquer Cancer: ASCO, 2020). Mylenoma begins in the plasma cells of bone marrow (National Cancer Institute, n.d.). Leukemia begins in the blood and bone marrow. Lymphomas start in the lymphatic system (Conquer Cancer: ASCO, 2020).

Cancer is a major public health issue around the world. GLOBOCAN statistics show that in 2018, there were an estimated 18.1 million new cancer cases (17 million excluding skin cancer non-melanoma) and 9.6 million cancer deaths (9.5 million excluding skin cancer non-melanoma) worldwide (Ferlay et al., 2018). The most prevalent cancers worldwide include (in order) lung cancer, female breast cancer, prostate cancer, colorectal cancer, stomach cancer, and liver cancer (Bray et al., 2018).

This essay aims to provide an overview of the effect of chronic stress and surgical-related acute stress on the progression and recurrence of cancer by critically exploring the evidence proposing the implications for cancer management.

This shall be done by drawing upon a small amount of literature investigating the link between chronic and surgical-related stress and progression and recurrence of cancer and providing a deeper understanding of the significant role stress plays in the development and recurrence of the disease and suggest ways in which cancer induced stress can be managed.

Stress and Allostatic Load

Stress can be defined as “a threat, real or implied, to the psychological or physiological integrity of an individual” (McEwen, 2000). It is a common aspect in life and significantly impacts the development and maintenance of health conditions and diseases (Kudielka & Kirschbaum, 2001). There are two types of stress: acute stress which tends to be short-lived and/or chronic stress which occurs over an extended time period (Segerstrom & Miller, 2004). Under chronic stress conditions, the body remains in a constant state of ‘overdrive’, with detrimental effects on regulation of stress response systems, as well as many organ systems (Moreno-Smith et al., 2010).

While the current literature contains many different definitions of stress and theories and frameworks attached to the concept of stress, this paper will focus on the work on Hans Selye (1907–1983) who is credited for bringing the concept of stress into medical discussions.

Selye’s general adaptation syndrome entails of an enlargement of the adrenal gland; atrophy of the thymus, spleen and other lymphoid tissue; and gastric ulcerations (Neylan, 1998). It proposes a three-stage pattern of response to stress: the alarm stage, the resistance stage, and the exhaustion stage (McEwen, 2005). During the alarm reaction stage, the adrenal medulla releases epinephrine and the adrenal cortex produces glucocorticoids, thus starting to restore homeostasis (Selye, 1950). This stage is characterized by a significant increase of the hypothalamic-pituitary-adrenal (HPA) axis activity (Ganzel et al., 2010). Restoration of biological responses to the stressor, i.e., homeostasis leads to the resistance stage where defense and adaptation are sustained, overt symptoms of stress decrease, or disappear, and body function is optimal (Ganzel et al., 2010), (Selye, 1950). The exhaustion stage only follows if the stressor persists and physiological defenses are exhausted whereby the overt symptoms will reappear (Ganzel et al., 2020). If there is no relief from the exhaustion stage, the consequences are illness and death (Selye, 1950).

More recent interpretations of Selye’s general adaptation syndrome have gone on to coin the term ‘allostatic state’ which occurs as a result of repeated exposure to stressors and, consequently, causes an imbalanced production of ‘stress hormones’ such as glucocorticoids and epinephrine (McEwen, 2005). Allostatic states can be prolonged for limited periods if food intake or stored energy such as fat can fuel the homeostatic mechanisms (McEwen & Wingfield, 2003). If the increased food intake continues, then symptoms of allostatic overload emerge (McEwen, 2005).

Allostatic load is defined as “the cost of chronic exposure to elevated or fluctuating endocrine or neural responses resulting from chronic or repeated challenges that the individual experiences as stressful” (Kudielka & Kirschbaum, 2001). Furthermore, if the additional load of stressors is ‘superimposed’, then allostatic load can increase significantly to become allostatic overload (McEwen, 2005). Simply put, allostatic load and allostatic overload, by extension, are the accumulative results of an allostatic state (McEwen, 2005).

Allostatic load and allostatic overload have negative effects to an individual’s predisposition to disease (McEwen, 2005). While the changes caused as a result of allostatic load and overload may be helpful in the short term, they have negative long-term consequences and/or costs for the individual, for example, prolonged high blood pressure causes wear and tear of the heart (Ganzel et al., 2010). In addition, allostatic load and overload could occur out of damage from the overproduction of the neurochemicals involved in the stress response, some of which are toxic, and through the enervation of stress response systems, as can occur in the immune system. This can bring about compromised immunocompetence in an individual, which is associated with higher levels of infection and vulnerability to cancer (Sapolsky & Donnelly, 1985). Increased load can also come through the inability to activate a particular stress response system, in which case other stress responses over-respond (McEwen, 1998).

Impact of Stress on the Progression of Cancer

Cancer progression is often collectively conceptualized and represented as a ‘journey’ in which a cell, with several possible intermediate steps along the way, evolves over time from a benign phenotype into an invasive or metastatic entity (Kumar & Weaver, 2009). The relationship between the cell’s biophysical properties and the Extracellular Matrix (ECM) creates a complex mechanical reciprocity between the cell and the ECM in which the capacity of the cell to exert contractile stresses against the extracellular environment matches the ECM’s elastic resistance to this deformation (Lelievre et al., 1998).

A possible correlation between stress and cancer progression is dependent on a theoretical cancer biobehavioral model (Costanzo et al., 2011). Stress perception stimulates the HPA axis and SNS, which can modulate cellular immune responses that can interrupt tumor surveillance and containment physiological processes, which can in turn promote tumor progression or recurrence (Todd et al., 2014).

Cellular immune indices, including natural killer (NK) and cytotoxic T lymphocyte (CTL) function, and macrophage motility and phagocytosis have been documented to be suppressed by psychological stress (Neeman & Ben-Eliyahu, 2013). In animal models, stress hormones, specifically catecholamines, opioids and glucocorticoids, have been repeatedly demonstrated to cause metastatic progression through different immunological and non-immunological mechanisms (Benish et al., 2008). In fact, in animals, it has been shown that even a single exposure to stress or stress hormones could increase cancer mortality during a crucial period of tumor progression (Inbar et al., 2011).

In addition, preclinical experimental studies have shown that substantial surgical-related acute stress also promotes tumor incidence and progression by suppressing the activities of natural killer (NK) and T cells, impairing the presentation of antigen, and improving the presence of T regulatory cells (Ben-Eliyahu et al., 1999).

There is strong existing evidence in support for links between psychological factors such as stress, depression and social isolation and cancer progression (Moreno-Smith et al., 2010). In addition, several researchers have studied the relationships between stress and cancers, such as prostate, breast, gastric, lung, and skin cancer, and have found evidence that chronic stress can cause tumorigenesis and promote cancer growth (Dai et al., 2020).

While the high prevalence of depression among cancer patients has been widely believed to be a reaction to the stress associated with a life-threatening diagnosis and cancer care (Spiegel & Giese-Davis, 2003), it has been hypothesized that inflammatory processes created secondary to treatment or tumor growth may contribute to depression pathogenesis, as well as fatigue and debilitation (Costanzo et al., 2011).

Inflammation, primarily known to confront and eliminate pathogens, is a protective response. It fulfils two corresponding functions, countering infection and promoting the growth of tissue, best evident in wound healing (Pribluda et al., 2013).

Notably, there is a relationship between inflammation and tumor progression which has been extended by recent data (Pribdula et al., 2013). There are many cancers that arise from infection sites, chronic irritation and inflammation. The tumor microenvironment, which is largely orchestrated by inflammatory cells, is now becoming apparent as an essential participant in the neoplastic process, promoting proliferation, survival and migration (Coussens & Werb, 2002).

The expression of stress-related pro-inflammatory genes in the circulating white blood cells can be increased by chronic stress and stress hormones, thus increasing the release of pro-inflammatory cells and the production of pro-inflammatory cytokines, and can activate the ageing-inflammatory response without triggering exogenous inflammation, leading to tumorigenesis promotion and metastasis (Bondar & Medzhitov, 2013).

While inflammation is emerging as one of the cancer characteristics (Hanahan and Weinberg, 2011), its role is not well understood in most tumors. Only a minority of solid tumors are associated with overt inflammation (Coussens & Werb, 2002), but long-term non-steroidal anti-inflammatory drugs (NSAID) treatment is remarkably effective in reducing mouse model intestinal tumorigenesis (Beazer-Barclay et al., 1996) and major human solid tumor-related mortality rates by up to 75% (Burn et al., 2011).

Impact of Stress on the Recurrence of Cancer

Stressor exposure has long been assumed to play a role in tumor activity recurrence. Psychological distress is an often-overlooked additional perioperative risk factor for cancer recurrence: starting with cancer diagnosis, patients experience anxiety, stress, and depression throughout and after surgical and adjuvant treatments, which translates, among other things, to activation of the sympathetic nervous system (SNS) and hypothalamic-pituitary-adrenal (HPA) axis (Thornton et al., 2010) and thus resulting in the release of stress hormones.

Survivors frequently report recurrent physical health problems, including fatigue and pain, irrespective of the form of cancer. Physical side effects of cancer and/or its treatment collectively represent a psychosocial strain on survivors that may seriously affect the mental health of survivors (Hall et al., 2016).

Somatic symptoms can affect psychosocial stress through patient cognitive evaluations of stimuli related to cancer diagnosis, care, and survivorship, according to biopsychosocial models of cancer distress (Osborn et al., 2006). These cognitions include interpretations, judgments, and opinions about events or signs related to cancer. Fear of recurrence or development is topmost among these, with moderate to high levels present in 30–70% of cancer survivors (Savard & Ivers, 2013). A clinical study by Simard et al. (2010) examining whether fear of recurrence or progression is an intermediate between the intensity of somatic symptoms and perceived stress among survivors of heterogeneous cancer found that cancer survivors with moderate to high levels of fear of recurrence or progression reported elevated levels of stress.

Even though some researchers have suggested that exposure to psychological stressors plays a greater role in cancer recurrence than the incidence of cancer, Costanzo et al.’s (2011) review of literature found that there is insufficient evidence at this time to conclude that there is a causal association between stressor exposure and/or stress response and cancer recurrence. The review suggests that further study is needed before any final conclusions can be drawn. Furthermore, it recommends that, based on the possibility of a relationship between stress and recurrence, cancer survivors should be advised to maintain a reasonable level of tension in their lives and be encouraged to use evidence-based therapies to relieve psychological stress (Costanzo et al., 2011).

Conclusion

In summary, the current research body offers clear evidence that chronic stress and surgical-related acute stress, and mechanisms of stress response, are correlated with key elements involved in the growth and development of tumors, cancer progression and recurrence. However, this premise is based on empirical findings in animal studies, and on indirect evidence and argumentations based on findings from human studies. It is recommended that more findings around the relationship between stress (chronic stress and surgical-related acute stress) and the growth and development of tumors, cancer progression and recurrence be derived from more direct evidence from human studies.

Furthermore, current literature primarily contains information on the relationship between stress and cancer progression and recurrence for prostate, breast, gastric, lung, and skin cancers, but has inadequate information on other forms and types of cancers. Thus, in order to assess if there could be a proper association between stress and the type of cancer, treatment exposures, stressors, stress response, and recurrence, future research should concentrate on several more types of cancers.